
Pulse Biosciences Enrolls First Patient in NANOCLAMP AF Study
Pulse Biosciences Enrolls First Patient in NANOCLAMP AF Study, Marking Major Milestone in Atrial Fibrillation Treatment Innovation Pulse Biosciences, Inc. (Nasdaq: PLSE), a company pioneering next-generation medical technologies through its proprietary nPulse™ platform and Nanosecond Pulsed Field Ablation™ (nsPFA™) energy,…












